Table 4. Clinicopathological characteristics of patients according to the expression of PD-L1.

Characteristics	PD-L1 positivein TCs (N=137)	PD-L1 negativein TCs (N=203)	P	PD-L1 positivein TIICs(N=204)	PD-L1 negativein TIICs(N=136)	P
Gender
Male	109(42.9%)	145(57.1%)	0.091	162(63.8%)	92(36.2%)	0.014
Female	28(32.6%)	58(67.4%)		42(48.8%)	44(51.2%)
Age
≤45	5(22.7%)	17(77.3%)	0.082	9(40.9%)	13(59.1%)	0.059
>45	132(41.5%)	186(58.5%)		195(61.3%)	123(38.7%)
WHO classification
Tubular adenocarcinoma	108(44.3%)	136(55.7%)	0.002	154(63.1%)	90(36.9%)	<0.001
Signet ring cell	5(13.9%)	31(86.1%)		10(27.8%)	26(72.2%)
Other	24(40.0%)	36(60.0%)		40(66.7%)	20(33.3%)
Histological grade
low grade	34(38.2%)	55(61.8%)	0.640	52(58.4%)	37(41.6%)	0.724
high grade	103(41.0%)	148(59.0%)		152(60.6%)	99(39.4%)
Tumor size
<5cm	31(26.3%)	87(73.7%)	<0.001	61(51.7%)	57(48.3%)	0.023
≥5cm	106(47.7%)	116(52.3%)		143(64.4%)	79(35.6%)
Vascular invasion
Negative	29(39.7%)	44(60.3%)	0.911	34(46.6%)	39(53.4%)	0.008
Positive	108(40.4%)	159(59.6%)		170(63.7%)	97(36.3%)
Neural invasion
Negative	52(41.9%)	72(58.1%)	0.640	74(59.7%)	50(40.3%)	0.927
Positive	85(39.4%)	131(60.6%)		130(60.2%)	86(39.8%)
Depth of invasion
T1/T2	8(23.5%)	26(76.5%)	0.036	18(52.9%)	16(47.1%)	0.376
T3/T4	129(42.2%)	177(57.8%)		186(60.8%)	120(39.2%)
Lymph metastasis
N0	34(52.3%)	31(47.7%)	0.028	43(66.2%)	22(33.8%)	0.260
N1/N2/N3	103(37.5%)	172(62.5%)		161(58.5%)	114(41.5%)
Distant metastasis
M0	132(40.6%)	193(59.4%)	0.574	196(60.3%)	129(39.7%)	0.590
M1	5(33.3%)	10(66.7%)		8(53.3%)	7(46.7%)
TNM stage
I-II	50(52.1%)	46(47.9%)	0.005	67(69.8%)	29(30.2%)	0.021
III-IV	87(35.7%)	157(64.3%)		137(56.1%)	107(43.9%)